Grail
Grail raises $390M Series D at $6.3B valuation
Quick Facts
Grail: Series D Funding Round
Grail has successfully raised $390M in Series D funding, reaching a valuation of $6.3B.
Company Overview
Multi-cancer early detection blood test
Funding Details
The Series D round was led by ARCH Venture Partners, with participation from Johnson & Johnson.
Company Information
- Headquarters: Menlo Park, CA
- Founded: 2016
- Employees: 500+
- Category: Biotech
Investment
Grail plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series D
- Johnson & Johnson: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
